Frontotemporal Dementia (FTD) Genetic Variants

Introduction

Frontotemporal Dementia (Ftd) Genetic Variants represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.

Frontotemporal dementia (FTD) is a spectrum of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes. Approximately 30-40% of FTD cases have a family history, with over 20 genes implicated in disease pathogenesis. This page summarizes the key genetic variants associated with FTD, their molecular mechanisms, clinical implications, and therapeutic relevance. ^{1Pathogenic VCP (p.Arg453Trp) variant in three siblings with frontotemporal dementia-amyotrophic lateral sclerosis spectrum: A Turkish familyPMID 41791136Open reference}

Overview

Frontotemporal dementia affects approximately 50,000-60,000 Americans, representing 10-20% of all dementia cases. The disease typically presents in mid-life (45-65 years) with changes in personality, behavior, and language. FTD is broadly classified into: ^{2A Novel Rare Homozygous R47C Variant in TREM2 with Frontal Variant Alzheimer's DiseasePMID 41817071Open reference}

• Behavioral variant FTD (bvFTD): Personality and behavioral changes

• Primary progressive aphasia (PPA): Language impairment

  • Semantic variant (svPPA)

  • Logopenic variant (lvPPA)

  • Nonfluent/agrammatic variant (nfvPTA)

The genetic architecture of FTD includes: ^{3Genome-wide association and functional genomic analyses of teat placement traits derived from robotic milking systems in American Holstein cattlePMID 41570900Open reference}

• Major causal genes: MAPT, GRN, C9orf72 (accounting for ~60% of familial FTD)

• Other causal genes: VCP, CHCHD10, TARDBP, FUS

• Risk genes: TMEM106B, APOE, ABCA7

Major Causal Genes

MAPT (Microtubule-Associated Protein Tau)

The MAPT gene on chromosome 17 encodes tau, a microtubule-stabilizing protein that is central to several neurodegenerative diseases. Over 50 pathogenic mutations cause FTD through tau dysfunction. ^{4Genetic Spectrum and Phenotypic Variability in Chinese Patients with Multisystem Proteinopathy and Related DisordersPMID 41737544Open reference}

Key features of MAPT mutations:

• Inheritance: Autosomal dominant

• Mechanisms: Altered splicing, reduced tau binding to microtubules, increased aggregation

• Phenotype: bvFTD, PSP, CBD overlap syndromes

Major MAPT mutations include:

• P301L: Most common, causes early onset bvFTD

• P301S: Aggressive phenotype

• K369I: Causes Lewy body pathology

• Exon 10 mutations: Lead to 3R/4R tau imbalance

The mutations affect:

1. Alternative splicing: Exon 10 mutations alter 3R/4R tau ratio

2. Phosphorylation: Hyperphosphorylation and aggregation

3. Microtubule binding: Impaired neuronal transport

4. Tau oligomers: Toxic oligomer formation

• MAPT Gene - Full gene page

• Tau Pathology - Tau mechanisms

GRN (Progranulin)

The GRN gene on chromosome 17 encodes progranulin, a secreted growth factor involved in cell proliferation, wound healing, and inflammation. Over 70 pathogenic mutations cause FTD through haploinsufficiency.

Key features of GRN mutations:

• Inheritance: Autosomal dominant

• Mechanism: Loss-of-function, reduced progranulin levels

• Penetrance: Age-dependent, ~90% by age 80

• Phenotype: bvFTD, PPA, CBS

GRN mutations lead to:

1. Progranulin deficiency: Reduced neurotrophic support

2. TDP-43 pathology: Accumulation of phosphorylated TDP-43

3. Lysosomal dysfunction: Impaired autophagy

4. Inflammation: Altered microglial function

The C9orf72 expansion can also cause FTD (often with ALS), demonstrating genetic overlap between these disorders.

• GRN Gene - Full gene page

C9orf72

As in ALS, C9orf72 hexanucleotide repeat expansions cause a significant proportion of familial FTD, often presenting as bvFTD or ALS/FTD.

Other Causal Genes

VCP (Valosin-Containing Protein)

The VCP gene on chromosome 9 encodes a AAA+ ATPase involved in protein degradation. Mutations cause inclusion body myopathy with early-onset Paget disease and FTD (IBMPFD/ALS4).

CHCHD10

The CHCHD10 gene encodes a mitochondrial protein involved in mitochondrial cristae organization. Mutations cause ALS/FTD with mitochondrial dysfunction.

TARDBP and FUS

As in ALS, mutations in TARDBP and FUS cause rare forms of FTD with TDP-43 or FUS pathology.

Risk Genes

TMEM106B

The TMEM106B gene on chromosome 7 encodes a lysosomal membrane protein. The rs3173615 variant (T185S) is a major genetic risk factor for FTD, particularly in GRN mutation carriers.

APOE

The APOE ε4 allele increases FTD risk approximately 2-3 fold, particularly in early-onset cases.

ABCA7

The ABCA7 gene variants increase FTD risk through effects on lipid metabolism and phagocytosis.

Genotype-Phenotype Correlations

Gene	Typical Phenotype	Pathology	Typical Age of Onset
MAPT	bvFTD, PSP	Tau	45-55 years
GRN	bvFTD, PPA	TDP-43	50-60 years
C9orf72	bvFTD, ALS/FTD	TDP-43 + DPR	50-60 years
VCP	bvFTD, IBM	TDP-43	40-50 years

Therapeutic Implications

Genetic testing is important for:

• Diagnosis: Confirming underlying etiology

• Family counseling: Identifying at-risk relatives

• Clinical trial enrollment: Genetic stratification

Emerging Therapies

1. GRN: Progranulin replacement, AAV-based gene therapy

2. MAPT: Tau-targeting immunotherapies, antisense oligonucleotides

3. C9orf72: ASOs targeting repeat transcripts, CRISPR approaches

Background

The study of Frontotemporal Dementia (Ftd) Genetic Variants has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• TBK1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: Mechanistic Insights into Impaired Autophagy and Proteostatic Failure. (2026 Mar 6) - Cells

• Pathogenic VCP (p.Arg453Trp) variant in three siblings with frontotemporal dementia-amyotrophic lateral sclerosis spectrum: A Turkish family. (2026 Mar 4) - Clinical neurology and neurosurgery

• A Novel Rare Homozygous R47C Variant in TREM2 with Frontal Variant Alzheimer’s Disease. (2026 Mar 1) - Neurology India

• Genome-wide association and functional genomic analyses of teat placement traits derived from robotic milking systems in American Holstein cattle. (2026 Mar) - Journal of dairy science

• Genetic Spectrum and Phenotypic Variability in Chinese Patients with Multisystem Proteinopathy and Related Disorders. (2026) - Degenerative neurological and neuromuscular disease